Samsung Biologics Begins Production of Eli Lilly's COVID-19 Antibody Treatment in the US
[Asia Economy Reporter Seo So-jung] Samsung Biologics (CEO Kim Tae-han) announced on the 17th that it plans to provide treatments more quickly to patients worldwide through a long-term production contract for a novel coronavirus (COVID-19) antibody therapy with Eli Lilly.
As Samsung Biologics mass-produces the COVID-19 neutralizing antibody therapy developed by Eli Lilly, it will be able to supply the treatment to patients in a timely manner. The two companies signed a contract for contract manufacturing (CMO) related to this in May.
David A. Ricks, Chairman of Eli Lilly, said, "The importance of neutralizing antibodies has been proven in the fight against COVID-19, and the biopharmaceutical industry continues fast and efficient collaboration to increase global supply of neutralizing antibodies. Through this contract with Samsung Biologics, we have not only stably reinforced production capacity but also can provide antibody treatments more effectively to patients worldwide."
Despite difficulties in securing raw materials stably due to the prolonged COVID-19 pandemic, Samsung Biologics strengthened collaboration with Eli Lilly and succeeded in producing and delivering the initial batch of medicines that meet the excellent medicine quality Good Manufacturing Practice (GMP) standards to Eli Lilly within five months of signing the contract. Additionally, Samsung Biologics significantly shortened the technology transfer period essential for biopharmaceutical production to about three months.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Kim Tae-han, President of Samsung Biologics, said, "Based on our goal to maximize customer satisfaction and our mission to bring an end to COVID-19, we were able to produce high-quality treatments in the shortest period ever and provide them to Eli Lilly. Through continuous cooperation, we will do our best to supply COVID-19 treatments stably and rapidly to patients worldwide."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
